Clinical trials: HCC
Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma
ETN101 is a multiple tyrosine kinase inhibitor (mTKI) targeting fms-like tyrosine kinase 3 (FLT3), receptor tyrosine kinase (KIT), vascular endothelial growth factor receptor 2 (VEGFR2), and platelet-derived growth factor…
- Conditions
- Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma, Liver Cancer
- Trial name
- NCT06326502
- Testing
- ETN101
- Where
- 2 sites in South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Etnova Therapeutics Corp.
HCC - Hepatocellular Carcinoma
Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma
ABSTRACT Objective: To detect presence of a residual tumor in patients of hepatocellular carcinoma (HCC) treated with Lipiodol based conventional trans arterial chemoembolization (cTACE) using density measurements on follow-up…
- Trial name
- NCT06602986
- Testing
- TACE
- Where
- Pakistan
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Pak Emirates Military Hospital
Liver Cancer
Association Between Autologous Transfusion and Recurrence-free Survival in Patients With HCC After Resection
This prospective non-randomized controlled trial aims to determine whether autotransfusion of red blood cells salvaged before liver resection is associated with the recurrence-free survival in patients with hepatocellular…
- Trial name
- AT/HCC (NCT02654028)
- Testing
- Autotransfusion, Control group
- Where
- China
- Volunteers
- 618 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma (HCC)
Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)
Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage, and early detection is critical for improving patient outcomes. Despite this, reliable non-invasive biomarkers for early-stage HCC are limited.
- Trial name
- CENTINEL (NCT07265271)
- Testing
- Small RNA sequence, Rt-qPCR
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Hepatocellular Carcinoma, Liver Cancer
Safety and Efficacy of DEB-TACE Performed With a Novel Reflux-control Microcatheter in Patients With HCC
BACKGROUND: Hepatocellular carcinoma is the fifth most frequent cancer in the world, with a diagnosis of more than 500,000 new cases per year.
- Trial name
- NCT04653701
- Testing
- Chemoembolization with preloaded microparticles 100 micron and reflux control microcatheter
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Juan José Ciampi Dopazo
Hepatocellular Carcinoma
Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 Resection
There are limited treatment options for HCC with high recurrence risk, and there is no consistent plan for adjuvant therapy after surgery. Hence an unmet clinical need.
- Trial name
- NCT05546619
- Testing
- HIPEC+tislelizumab + targeted therapy
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sulai Liu
Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocellular Carcinoma
Application of Super-Resolution Ultrasound (SRUS) in Liver Tumor
The macroscopic vascular supply of liver tumors varies considerably according to histological subtype, lesion size, and disease stage.
- Conditions
- Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocellular Carcinoma, Hepatic Hemangioma, Focal Nodular Hyperplasia
- Trial name
- SRUS (NCT07707661)
- Testing
- Perform super-resolution ultrasound imaging on the study population
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
Tumor Growth Factors in Hepatocellular Carcinoma
Malignant cells frequently produce many tumor growth factors to autocidal or endocrinal proliferate growth, metastasis,or angiogenesis about tumor cells.
- Trial name
- NCT00764140
- Testing
- tumor growth factor concentration
- Where
- Taiwan
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
HCC, MASLD
Accumulation of Lipid Droplets as an Underlying Cause of the Progression of Fatty Liver Disease to Liver Cancer
Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently the leading cause of chronic liver disease, accounting for an increasing burden of cirrhosis, hepatocellular carcinoma (HCC), and related mortality…
- Trial name
- NCT07775716
- Testing
- Comprehensive Genomic and Transcriptomic Profiling, Patient-Derived Human Liver Organoid (HLO) Development, AI-Driven Digital Pathology (HistoIndex)
- Where
- Italy
- Volunteers
- 35,500 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Hepatocellular Carcinoma
A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment of Inoperable HCC
The trial is a multicentre, prospective, randomised controlled, unblinded, parallel-group superiority trial of SBRT versus standard TAE/TACE for the curative treatment of inoperable HCC treated with a TAE/TACE incomplete cycle.
- Trial name
- NCT02323360
- Testing
- SBRT, TACE
- Where
- Italy
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Istituto Clinico Humanitas
HCC, Tace
Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment
Study Objectives： Atezolizumab (anti-programmed death-ligand 1; anti-PD-L1) combined with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) or Durvalumab (anti-programmed death-ligand 1; anti-PD-L1) combined with…
- Conditions
- HCC, Tace, Immunotherapy
- Trial name
- EXPECT (NCT07168668)
- Testing
- Transarterial chemoembolization, durvalumab and tremelimumab
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Non-small Cell Lung Cancer, Esophageal Cancer
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery.
- Conditions
- Non-small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT02838836
- Testing
- Study sample collection
- Where
- United States
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Hepatitis B, Liver Cirrhosis
Application of HBV Rapid Tests as a Tool for Wide-Use Screening
With over 280 000 chronic carriers, 2,500 new annual cases and 1,300 deaths each year, hepatitis B is currently a frequent and potentially severe disease in France, despite efforts towards prevention and effective care.
- Conditions
- Hepatitis B, Liver Cirrhosis, Carcinoma, Hepatocellular
- Trial name
- OPTISCREEN-B (NCT01767597)
- Testing
- ELISA testing, Rapid testing
- Where
- 5 sites in France
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Cirrhosis, Cirrhosis, Liver
Volatile Organic Compounds for the Assessment of Liver Disease
This study aims to determine whether a breath test could be used for early detection of hepatic fibrosis, cirrhosis or hepatocellular carcinoma.
- Conditions
- Cirrhosis, Cirrhosis, Liver, Fibrosis, Liver, Hepatocellular Carcinoma
- Trial name
- VOCAL (NCT04620538)
- Testing
- Breath Analysis
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Brest Cancer, Lung Cancer (NSCLC)
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients.
- Conditions
- Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers
- Trial name
- CCANED-CIPHER (NCT06717295)
- Testing
- DiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
- Where
- 4 sites in Argentina, Nigeria and 1 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Javier Toledo
Hepatocellular Carcinoma
A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection
Hepatic resection is the most effective curative treatment for resectable HCC, whereas frequent recurrence usually impaired the efficacy of hepatic resection and contributed poor survivals.
- Trial name
- NCT03914352
- Testing
- PD-1 antibody, TACE
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cancer Hospital of Guangxi Medical University
Hepatocellular Carcinoma
Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood
By collecting blood samples from liver cancer patients and healthy individuals, and comparing the blood protein profiles of the two, the biomarkers for early diagnosis and tissue traceability were identified to accurately…
- Trial name
- NCT06544083
- Testing
- Proteomics
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma, Glioblastoma
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
The primary objective of this study is to evaluate the safety and clinical activity of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.
- Conditions
- Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma, Colon Cancer
- Trial name
- NCT04270461
- Testing
- NKG2D-based CAR T-cells
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Jiujiang University Affiliated Hospital
Hepatitis B,Chronic, Carcinoma,Hepatocellular
The Development of Diagnostic Biomarker Panels for Hepatitis and Liver Cancer
More recent studies have shown that the HBV-infected population has a greater risk of development of hepatocellular carcinoma. Nevertheless, there are still a significant number of people chronically infected by HBV who do not…
- Trial name
- NCT01310062
- Where
- 8 sites in Malaysia
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Ministry of Health, Malaysia
Carcinoma, Hepatocellular, Liver Dysfunction
Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma
The purpose of this study is to determine whether the global and segmental hepatic uptake and excretion of Gd-EOB-DTPA on Gd-EOB-DTPA-enhanced liver MRI correlates with standard liver function test results in the patients with…
- Trial name
- LiFE (NCT01490203)
- Testing
- Gd-EOB-DTPA, MRI
- Where
- 4 sites in South Korea
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital